Resistance of uveal melanoma to the interstrand cross-linking agent mitomycin C is associated with reduced expression of CYP450R

British Journal of Cancer

Volumn 104, Issue 7, 2011, Pages 1098-1105

  Gravells, P ^a   Hoh, L ^a   Canovas, D ^a   Rennie, I G ^a   Sisley, K ^a   Bryant, H E ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

cisplatin; CYP450R; mitomycin C; replication inhibitor; uveal melanoma

Indexed keywords

CISPLATIN; CYTOCHROME P450 REDUCTASE; HYDROXYUREA; MITOMYCIN C;

ARTICLE; CELL CULTURE; COMET ASSAY; CONTROLLED STUDY; DNA CROSS LINKING; DNA DAMAGE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UVEA MELANOMA; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CROSS-LINKING REAGENTS; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTONES; HUMANS; MALE; MELANOMA; MITOMYCIN; NADPH-FERRIHEMOPROTEIN REDUCTASE; UVEAL NEOPLASMS;

EID: 79953230812     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.56     Document Type: Article

References (32)

1. Baumann RP, Hodnick WF, Seow HA, Belcourt MF, Rockwell S, Sherman DH, Sartorelli AC (2001) Reversal of mitomycin C resistance by overexpression of bioreductive enzymes in Chinese hamster ovary cells. Cancer Res 61: 7770-7776 (Pubitemid 33049363)
2. Bedikian AY (2006) Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin 46: 151-166 (Pubitemid 44124237)
3. Bizanek R, McGuinness BF, Nakanishi K, Tomasz M (1992) Isolation and structure of an intrastrand cross-link adduct of mitomycin C and DNA. Biochemistry 31: 3084-3091
4. Chalasani R, Giblin M, Conway RM (2006) Role of topical chemotherapy for primary acquired melanosis and malignant melanoma of the conjunctiva and cornea: review of the evidence and recommendations for treatment. Clin Exp Ophthal 34: 708-714 (Pubitemid 44363625)
5. Chevillard S, Vielh P, Vallidire P, Robert J, Marie JP (1996) A study of the expression of MDR1 gene in solid tumors. Initial results of a multicenter evaluation. Bull Cancer 83: 626-633 (Pubitemid 26273030)
6. Coupland SE, Anastassiou G, Stang A, Schilling H, Anagnostopoulos I, Bornfeld N, Stein H (2000) The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. J Pathol 191: 120-126 (Pubitemid 30394887)
7. Coupland SE, Bechrakis N, Schuler A, Anagnostopoulos I, Hummel M, Bornfeld N, Stein H (1998) Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma. Br J Ophthalmol 82: 961-970 (Pubitemid 28408159)
8. Cowen RL, Patterson AV, Telfer BA, Airley RE, Hobbs S, Phillips RM, Jaffar M, Stratford IJ, Williams KJ (2003) Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts. Mol Cancer Ther 2: 901-909
9. Dayani PN, Gould JE, Brown DB, Sharma KV, Linette GP, Harbour JW (2009) Hepatic metastasis from uveal melanoma: angiographic pattern predictive of survival after hepatic arterial chemoembolization. Arch Ophthalmol 127: 628-632
10. Elshaw SR, Sisley K, Cross N, Murray AK, MacNeil SM, Wagner M, Nichols CE, Rennie IG (2001) A comparison of ocular melanocyte and uveal melanoma cell invasion and the implication of alpha1beta1, alpha4beta1 and alpha6beta1 integrins. Br J Ophthalmol 85: 732-738 (Pubitemid 32554254)
11. Gan Y, Mo Y, Kalns JE, Lu J, Danenberg K, Danenberg P, Wientjes MG, Au JL (2001) Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors. Clin Cancer Res 7: 1313-1319 (Pubitemid 32708686)
12. Harbour (2003) Clinical Overview of Uveal Melanoma: Introduction to Tumors of the Eye. Ocular Oncology. Marcel Dekker: New York
13. Inskip PD, Devesa SS, Fraumeni Jr JF (2003) Trends in the incidence of ocular melanoma in the United States, 1974-1998. Cancer Causes Control 14: 251-257 (Pubitemid 36656335)
14. Iyer VN, Szybalski W (1963) A molecular mechanism of mitomycin action: linking of complementary DNA strands. Proc Natl Acad Sci USA 50: 355-362
15. Juul T, Malolepszy A, Dybkaer K, Kidmose R, Rasmussen JT, Anderson GR, Johnsen HR, Jorgensen JE, Anderson SU (2010) The in vivo toxicity of hydroxyurea depends on its direct target catalase. J Biol Chem 285: 21411-21415
16. Kujala E, Makitie T, Kivela T (2003) Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 44: 4651-4659 (Pubitemid 37315273)
17. McNamara M, Clynes M, Dunne B, NicAmhlaoibh R, Lee WR, Barnes C, Kennedy SM (1996) Multidrug resistance in ocular melanoma. Br J Ophthalmol 80: 1009-1012 (Pubitemid 26413706)
18. Melichar B, Voboril Z, Lojik M, Krajina A (2009) Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbazine. Hepatogastroenterology 56: 1157-1162
19. Myatt NM, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL, Plowman PN (1997) The ex vivo chemosensitivity profile of choroidal melanoma. Anticancer Drugs 8: 756-762 (Pubitemid 27451817)
20. Neale MH, Myatt NM, Khoury GG, Weaver P, Lamont A, Hungerford JL, Kurbacher C (2001) Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma. Mel Res 11: 601-609 (Pubitemid 33152351)
21. O'Dwyer PJ, Perez RP, Yao KS, Godwin AK, Hamilton TC (1996) Increased DT-diaphorase expression and crossresistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines. Biochem Pharmacol 52: 21-27
22. Patel KA, Edmondson ND, Talbot F, Parsons MA, Rennie IG, Sisley K (2001) Prediction of prognosis in patients with uveal melanoma using fluorescence in situ hybridisation. Br J Ophthalmol 85: 1440-1444 (Pubitemid 34032910)
23. Pichierri P, Averbeck D, Rosselli F (2002) DNA cross-link-dependent RAD50/MRE11/NBS1 subnuclear assembly requires the Fanconi anemia C protein. Hum Mol Genet 11: 2531-2546 (Pubitemid 35174684)
24. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273: 5858-5868 (Pubitemid 28124064)
25. Schmittel A, Scheulen ME, Bechrakis NE, Strumberg D, Baumgart J, Bornfeld N, Foerster MH, Thiel E, Keilholz U (2005) Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. Melanoma Res 15: 205-207 (Pubitemid 40839469)
26. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279
27. Singh AD, Bergman L, Seregard S (2005) Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am 18: 75-84, viii (Pubitemid 40348812)
28. Suresh Kumar G, Lipman R, Cummings J, Tomasz M (1997) Mitomycin C-DNA adducts generated by DT-diaphorase. Revised mechanism of the enzymatic reductive activation of mitomycin C. Biochemistry 36: 14128-14136 (Pubitemid 27509848)
29. Tomasz M, Chowdary D, Lipman R, Shimotakahara S, Veiro D, Walker V, Verdine GL (1986) Reaction of DNA with chemically or enzymatically activated mitomycin C: isolation and structure of the major covalent adduct. Proc Natl Acad Sci USA 83: 6702-6706 (Pubitemid 16002302)
30. Van Der Pol JP, Blom DJ, Flens MJ, Luyten GP, de Waard-Siebinga I, Koornneef L, Scheper RJ, Jager MJ (1997) Multidrug resistance-related proteins in primary choroidal melanomas and in vitro cell lines. Invest Ophthalmol Vis Sci 38: 2523-2530 (Pubitemid 27492754)
31. Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, Lutz JM, Paci E (2008) Survival in patients with uveal melanoma in Europe. Arch Ophthalmol 126: 1413-1418
32. Vogl T, Eichler K, Zangos S, Herzog C, Hammerstingl R, Balzer J, Gholami A (2007) Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol 133: 177-184 (Pubitemid 46144093)